Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$275.36M+221.32%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Dean Halbert
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,846
- Beta
- 0.70
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 4.15
Financials
Revenue
$275.36M+221.3%Net Income
$15.25M-59.8%EBITDA
$26.12M-48.7%Free Cash Flow
$-39.72MEPS (diluted)
$0.05-97.5%Shares Outstanding (diluted)
295.14M+1588.5%Operating Expenses
$162.97MCash & Debt
$767.38MReturn of Capital
$10.01MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $812.03M | $-537.96M | $-1.90 |
| 2024 | $412.26M | $-281.89M | $-1.35 |
| 2023 | $306.13M | $-341.42M | $-1.82 |
| 2022 | $258.49M | $-320.83M | $-1.57 |
Valuation
CAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
55+10.00%Social Signal Score
Mentions (22)
- 4chan /biz/biz·6d ago·Neutral
>>62908032 Here's something the doctors will not tell you: The gene therapies under trial can add significantly to your life expectancy. Do Not Wait to complete mainline chemo regimens before waitlisting for the trials or you won't live long enough to get on them or you'll have a disqualifying event like a stroke or something from the chemo. Do not wait for your oncologist to refer you to a trial. That's not a thing. You have to go out and get them yourself. Trust that you need to be looking on
View source ↗ - News (RSS)fool·17d ago·Positive
Caris Life (CAI) Q3 2026 Earnings Call Transcript Clinical volume surged while capacity constraints remain a watch point.
View source ↗ - News (RSS)zerohedge·17d ago·Neutral
…r the mobile-app marketing company’s third-quarter results beat expectations and it gave an outlook that is above the analyst consensus estimate.Caris Life Sciences (CAI) slumps 14% after providing results and guidance; analysts note a lack of volume upside for the fourth quarter as a key concern.Cava (CAVA) sinks 8% on concern the company’s momentum is slowing despite the popularity of new dishes such as salmon bowls and barbecue pita chips.Celsius (CELH) rises 6% after the energy drink’s reven…
View source ↗ - News (RSS)seekingalpha·17d ago·Positive
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
Caris Life Sciences Q3 Earnings Call Highlights Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company also reported lower quarterly profit as it increased spending on its sales force, marketing and new tests.
View source ↗ - Newszacks.com·18d ago·Positive
Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.
View source ↗ - Newsprnewswire.com·18d ago·Positive
…ses 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29% IRVING, Texas, Nov. 4, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period.
View source ↗ - 4chan /biz/biz·20d ago·Neutral
>>62847808 >Caris kek i used to work there i didnt know they went public
View source ↗ - Newsprnewswire.com·34d ago·Neutral
…e insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth. The campaign emphasizes that while modern technology can measure nearly every aspect of ath…
View source ↗ - Newsprnewswire.com·38d ago·Neutral
Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November 4, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.
View source ↗ - Newsprnewswire.com·39d ago·Negative
…ication and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present eight posters at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain. The research showcases the expanding impact of artificia…
View source ↗ - Newsinvestors.com·51d ago·Positive
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
View source ↗ - News (RSS)yahoo·61d ago·Positive
Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
View source ↗ - Newsseekingalpha.com·66d ago·Positive
…owth With Room To Run Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships, leveraging them into new tests that I believe should increase their shareholder value in the long run. CAI's Detect broadens its growth potential. However, we still need to see if their cash-pay adoption and marketing expenses pay off as intended.
View source ↗ - Newszacks.com·67d ago·Neutral
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock? Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsprnewswire.com·75d ago·Positive
… through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner.
View source ↗ - News (RSS)economictimes·81d ago·Neutral
NCDEX, CAI join hands to boost India’s cotton derivatives market NCDEX and the Cotton Association of India have signed a five-year partnership to expand cotton derivatives participation, improve price discovery and strengthen risk management through greater futures adoption across India’s cotton value chain.
View source ↗ - Newsproactiveinvestors.co.uk·87d ago·Neutral
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for pancreatic cancer. The research, published in npj Precision Oncology, describes the development and validation of the Caris AI Insights model using outcomes from patients receiving FOLFIRINOX or gemcitabine plus nab-p…
View source ↗ - Newsprnewswire.com·87d ago·Neutral
…y, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies. The study demonstrate…
View source ↗ - News (RSS)businessinsider·88d ago·Neutral
Associa’s Crystal Webb Named to 2026 CAI Keystone Emerging Leaders Under 40 Class <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left" style="padding-left:0px;">DALLAS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=d2sTbunw7wDzZkkKaNuYPUoVfvV9EKEsSvPJtu3WEcK2VfcIjhSUPQrQV_ibIKnhhLf7nMvPno5GM6H4m0cikg==" rel="nofollow"...
View source ↗ - Newsdefenseworld.net·97d ago·Neutral
Head to Head Comparison: Caris Life Sciences (CAI) vs. Its Competitors Caris Life Sciences (NASDAQ: CAI - Get Free Report) is one of 110 public companies in the "Life Sciences Tools and Services" industry, but how does it contrast to its rivals? We will compare Caris Life Sciences to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, dividends and institutional ownership.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $0.06 per share
Typical surprise +84.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.05 vs $0.03beat
- Wed, Aug 5$-0.00 vs $0.01miss
- Thu, May 7$-0.00 vs $-0.02beat
- Thu, Feb 26$0.28 vs $0.01beat
- Wed, Nov 5$0.08 vs $-0.08beat
- Tue, Aug 12$-0.54 vs $-0.21miss
Estimates and results for CAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAI officers and directors.
- Bought
- $2.4m
- Sold
- $28.9m
6 trades
7 trades
- Denton John Russelsold
- Brille Brian Jsold
- Spetzler David Baxleysold
- Spetzler David Baxleysold
- Spetzler David Baxleysold
- Halbert Jonbought
- Vacirca Jeff Lbought
- Power Luke Thomassold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
